奥马珠单抗治疗过敏性哮喘的研究进展  

Research progress of omazumab in the treatment of allergic asthma

作　　者：张建涛[1] ZHANG Jian-tao(Department of 2nd Internal Medicine,Public Security Hospital of Tianjin,Tianjin 300042,China)

机构地区：[1]天津市公安医院内二科,天津300042

出　　处：《中国城乡企业卫生》2021年第12期66-68,共3页Chinese Journal of Urban and Rural Enterprise Hygiene

摘　　要：过敏性哮喘是由多种细胞,如嗜酸性粒细胞、肥大细胞、T淋巴细胞、中性粒细胞、气道上皮细胞等,与细胞组分参与的气道慢性炎症为特征的异质性疾病,其慢性持续性和频繁的急性发作严重影响了患者的生活质量,过敏性哮喘目前尚不能治愈,需要长期规范化治疗,给患者和家庭带来较大的经济负担和心理负担。奥马珠单抗是一种重组人源化抗IgE单克隆抗体,被全球哮喘防治倡议(GINA)推荐为IgE介导的中重度过敏性哮喘的靶向治疗药物。本文对近年来奥马珠单抗用于治疗过敏性哮喘的临床应用研究成果进行综述,从奥马珠单抗治疗中重度过敏性哮喘的作用机理、疗效、副作用和成本效益等方面进行分类总结阐述。近年来多项临床试验研究均已证明,奥马珠单抗对于难以控制的中重度哮喘具有很好的治疗效果,且其不良反应小,与其他药物无相互作用,能够明显缓解哮喘发作症状、提高患者生活质量、减少急性发作、节约医疗资源成本。但奥马珠单抗治疗费用较高,在临床应用实践过程中,应充分考虑不同患者病情的适用性和经济承受能力,从而更好地维护患者身体健康。Allergic asthma is a heterogeneous disease characterized by a variety of cells,such as eosinophils, mast cells, T lymphocytes, neutrophils, airway epithelial cells, and chronic airway inflammation participated by cell components. Its chronic persistence and frequent acute attacks seriously affect the quality of life of patients. Allergic asthma cannot be cured at present,It needs long-term standardized treatment,which brings great economic and psychological burden to patients and families.Omazumab is a recombinant humanized anti IgE monoclonal antibody. It is recommended by the Global Initiative for Asthma(GINA)as a targeted therapeutic drug for IgE mediated moderate and severe allergic asthma. This paper reviews the clinical application research results of omalizumab in the treatment of allergic asthma in recent years,and classifies and expounds the mechanism,efficacy,side effects and cost-effectiveness of omalizumab in the treatment of moderate and severe allergic asthma. In recent years,a number of clinical trials have proved that omazumab has a good therapeutic effect on moderate and severe asthma that is difficult to control,with small side effects and no interaction with other drugs. It can greatly alleviate the symptoms of asthma attack,improve the quality of life of patients,reduce acute attack and save the cost of medical resources. However,the treatment cost of omazumab is high. In the process of clinical application,the applicability and economic affordability of different patients should be fully considered,so as to better maintain the health of patients.

关 键 词：过敏性哮喘 奥马珠单抗 发作 研究进展 

分 类 号：R5[医药卫生—内科学]